Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00085-1519-03 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 In Use
00085-1417-03 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov 2, 2012 In Use
00085-1425-03 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 In Use
00085-1366-05 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov 2, 2012 In Use
00085-1366-02 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 May 29, 2015 In Use
00085-1430-03 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 In Use
00085-1425-02 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 Oct 22, 2014 In Use
00085-1430-01 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 May 29, 2015 In Use
54868-4142-00 54868-4142 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jun 29, 2005 In Use
00085-1519-01 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 Oct 22, 2014 In Use
57894-0450-01 57894-0450 Teclistamab TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
50242-0917-01 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 18, 2016 In Use
50242-0917-86 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Aug 11, 2016 In Use
50242-0918-01 50242-0918 Atezolizumab TECENTRIQ 840.0 mg/14mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Mar 8, 2019 In Use
50242-0918-86 50242-0918 Atezolizumab TECENTRIQ 840.0 mg/14mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Mar 8, 2019 Mar 18, 2019 In Use
50242-0933-01 50242-0933 Atezolizumab and hyaluronidase-tqjs Tecentriq Hybreza 1875.0 mg/15mL, 30000.0 U/15mL Immunotherapy Checkpoint Inhibitor PD-L1 Subcutaneous Sep 12, 2024 In Use
50242-0933-86 50242-0933 Atezolizumab and hyaluronidase-tqjs Tecentriq Hybreza 1875.0 mg/15mL, 30000.0 U/15mL Immunotherapy Checkpoint Inhibitor PD-L1 Subcutaneous Sep 12, 2024 In Use
83205-0001-02 83205-0001 Afamitresgene autoleucel TECELRA 10000000000.0 1/1 Immunotherapy T Cell Receptor (TCR) MAGE-A4 Intravenous Aug 2, 2024 In Use
71287-0219-02 71287-0219 brexucabtagene autoleucel TECARTUS 2000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Jul 24, 2020 In Use
71287-0220-02 71287-0220 brexucabtagene autoleucel TECARTUS 1000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Oct 1, 2021 In Use
72607-0100-00 72607-0100 tazemetostat TAZVERIK 200.0 mg/1 Chemotherapy Enzyme Inhibitor EZH2 Oral Jan 23, 2020 In Use
00075-8005-01 00075-8005 Docetaxel Taxotere Chemotherapy Antimitotic Agent Taxane Intravenous May 4, 2012 Dec 23, 2013 No Longer Used
00075-8001-20 00075-8001 Docetaxel Taxotere Chemotherapy Antimitotic Agent Taxane Intravenous Dec 22, 2011 Jun 30, 2013 No Longer Used
00075-8004-04 00075-8004 Docetaxel Taxotere 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug 2, 2010 Apr 30, 2021 No Longer Used

Found 11120 results — Export these results